Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2018 April;70(2) > Minerva Urologica e Nefrologica 2018 April;70(2):162-78

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA UROLOGICA E NEFROLOGICA

Rivista di Nefrologia e Urologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

REVIEW  


Minerva Urologica e Nefrologica 2018 April;70(2):162-78

DOI: 10.23736/S0393-2249.17.02882-X

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

A systematic review of preclinical studies on therapeutic potential of stem cells or stem cells products in peritoneal fibrosis

Sudabeh ALATAB 1 , Iraj NAJAFI 2, Rasha ATLASI 3, 4, Gholamreza POURMAND 1, Ozra TABATABAEI-MALAZY 5, 6, Naser AHMADBEIGI 7

1 Department of Urology, Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran; 2 Department of Nephrology, Nephrology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; 3 Evidence-Based Practice Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 4 Department of Medical Library and Information Science, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran; 5 Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 6 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 7 Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran


PDF  


INTRODUCTION: Peritoneal fibrosis remains a serious complication of long-term peritoneal dialysis. Stem cell therapy is an innovative field of scientific investigation with potential for clinical application. Here, we systematically reviewed the studies to determine whether stem cell based therapy could improve the peritoneal fibrosis in experimental models of peritoneal fibrosis.
EVIDENCE ACQUISITION: Our systematic search of PubMed, Scopus, Web of Science, and Cochrane Library yield 5219 article. After screening for eligibility, in vivo, experimental, interventional studies using stem cells in animal models of peritoneal fibrosis; 11 articles were included. The studies underwent comprehensive review, quality assessment, and data extraction.
EVIDENCE SYNTHESIS: Mesenchymal stem cells were the most used type (90.9%) originated either from bone marrow (70%), adipose tissue (20%), or umbilical cord (10%). In 90.9% of studies, stem cells were injected after peritoneal insult and 63.6% of studies used the intraperitoneal injection route. Eight studies met the ≥50% of criteria indicated by ARRIVE recommendation. Information regarding the nature of ethical review permissions, species, strain and gender, dose, route and duration of treatment, was stated by all studies; 81.8% of the studies reported the number of animals in each group. Adverse events were reported in one study. Improvement in histological parameters including attenuation of submesothelial thickness (100%), inflammation (62.5%), angiogenesis (60%), and fibrosis (85.7%) was reported after stem cell therapy. Peritoneal permeability function by assessing the ultrafiltration, glucose transport and solute permeability was improved in all studies. Stem cell treatment resulted in mesothelial recovery in 100% of studies.
CONCLUSIONS: In preclinical studies, the use of stem cells is associated with improved peritoneal fibrosis. This may provide an important foundation to support future translational clinical research using stem cell therapy to repair the injured peritoneum and modulate immune responses in PD patients.


KEY WORDS: Peritoneal fibrosis - Models, animal - Cell- and tissue-based therapy - Stem cells - Review literature as topic

inizio pagina

Publication History

Issue published online: March 29, 2018
Article first published online: March 30, 2017
Manuscript accepted: March 10, 2017
Manuscript revised: March 7, 2017
Manuscript received: December 26, 2016

Per citare questo articolo

Alatab S, Najafi I, Atlasi R, Pourmand G, Tabatabaei-Malazy O, Ahmadbeigi N. A systematic review of preclinical studies on therapeutic potential of stem cells or stem cells products in peritoneal fibrosis. Minerva Urol Nefrol 2018;70:162-78. DOI: 10.23736/S0393-2249.17.02882-X

Corresponding author e-mail

sudabehalatab@yahoo.com